A Stanford analysis of over 53,000 U.S. adults with type‑2 diabetes found metformin users had a 39% lower risk of death in the year after a COVID‑19 infection.
A Stanford analysis of over 53,000 U.S. adults with type‑2 diabetes found metformin users had a 39% lower risk of death in the year after a COVID‑19 infection.